An FDA Panel Just Backed Compounded BPC-157. That Is Not the Same as Approval
On 23 and 24 July, an FDA advisory committee looked at seven peptides and recommended that pharmacies be allowed to compound several of them. The vote is not binding, and the evidence gap has not moved.
Tuesday, August 11, 2026/3 min read
On 23 and 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee met to consider whether seven peptides should be eligible for compounding by pharmacies under federal law. Among them were BPC-157 and Semax, two compounds that have spent years circulating through gyms, longevity clinics and Telegram channels with essentially no human evidence behind them.
The panel recommended that several be permitted, including BPC-157, KPV, TB-500 and MOTS-c. The reaction split immediately into celebration and alarm, and both reactions overstated what happened.
What the vote does and does not do
Three things are worth separating.
The vote is advisory. The committee recommends. The FDA decides, and it is not obliged to follow. Historically it usually does, but that is a pattern rather than a rule, and no rule has changed yet.
Compounding is not approval. Permitting a substance on the 503A bulk drug substances list means a licensed pharmacy may prepare it for an individual patient with a prescription. It does not mean the compound has demonstrated efficacy for anything, and it does not create a labelled indication. It is a supply-chain permission, not a clinical endorsement.
The status quo was worse than either outcome. These peptides had been sitting in Category 2 of the bulks list, flagged for safety concerns including impurities, which left them in a grey zone: not clearly prohibited, not authorised, and therefore sold anyway through channels with no oversight whatsoever.
The argument the panel was actually weighing
The case for permitting compounding is a harm-reduction one, and it is stronger than critics allow.
People are already using these peptides in large numbers. They are buying them from grey-market suppliers with no sterility testing, no purity verification and no dosing guidance, and injecting them at home. A compounding pharmacy is at least a regulated facility, with a pharmacist, a prescription and a traceable product.
There is a second economic argument. These are off-patent or unpatentable molecules. Nobody will fund a Phase 3 trial for a compound they cannot own, so the evidence gap is partly a market failure rather than a scientific verdict.
The case against is straightforward. Peer-reviewed reviews of BPC-157 keep concluding the same thing: interesting animal data, some plausible mechanisms around angiogenesis and tissue repair, and no adequate human pharmacokinetic or pharmacodynamic profiling. Nobody knows what repeated long-term exposure does. Permitting easier access to an untested injectable normalises it, and normalisation is hard to reverse.
The political layer, stated plainly
This decision arrived in a live political argument about medical freedom and regulatory reach, and was widely reported as a win for that agenda within the current US health administration.
That context is worth knowing because it affects how the decision will be read, but it does not settle the science either way. A recommendation can be politically motivated and still be the right call, or scientifically cautious and still be wrong. The evidence question stands independently, and on the evidence question nothing new arrived in July.
What this means for someone considering peptides
Four practical points.
- Compounded does not mean studied. If a clinic tells you BPC-157 is now FDA-cleared, that is false. A pharmacy may be permitted to make it. That is all.
- It is still prescription-mediated. Which means a clinician takes responsibility, and you should ask what their reasoning is beyond the compound being popular.
- Pharmacy sourcing is a genuine improvement on the grey market. If you are going to use these things regardless, this route is safer than an unlabelled vial, and it is not close.
- The unknowns are still unknown. Particularly relevant for anyone with a cancer history, given that the mechanisms most often cited for BPC-157 involve promoting blood vessel growth and tissue proliferation. That is not a proven risk. It is an unexamined one, which is not reassuring.
The wider pattern
This is the second time in two years that regulators have been forced to respond to demand that ran ahead of evidence. The first was compounded semaglutide, where a shortage created a vast unregulated supply and then a counterfeit problem that regulators are still cleaning up.
The lesson both times is the same. When people want something badly enough, prohibition does not remove it from the market, it removes it from oversight. Whether the answer is to bring it inside the tent or hold the line is a real policy disagreement, and reasonable people are on both sides.
What is not in dispute is the state of the evidence. If you want the framework for reading these claims yourself, we set it out in what a peptide actually is, and it starts with a simple question: how many humans, for how long?
Published in The Outspoken Digest
Editorial desk
Outspoken Digest Health DeskMedicine, public health and the research behind the headlines, read carefully.
Newsletter
The Digest, in your inbox
One edition, sent when it is ready. No noise, and your address is never passed on.
Read Next
More Health →
